TWP
CHRS icon

Tyche Wealth Partners’s Coherus Oncology CHRS Stock Holding History

Tyche Wealth Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407K Buy
240,868
+20,000
+9% +$35.5K 0.06% 229
2025
Q4 		$314K Buy
220,868
+25,000
+13% +$36.4K 0.05% 257
2025
Q3 		$321K Sell
195,868
-14,000
-7% -$15.6K 0.06% 223
2025
Q2 		$153K Sell
209,868
-55,898
-21% -$48.3K 0.03% 286
2025
Q1 		$214K Sell
265,766
-1,000
-0.4% -$1.15K 0.05% 263
2024
Q4 		$368K Buy
266,766
+50,864
+24% +$57.1K 0.08% 184
2024
Q3 		$225K Hold
215,902
– – 0.05% 254
2024
Q2 		$374K Hold
215,902
– – 0.09% 161
2024
Q1 		$516K Hold
215,902
– – 0.13% 133
2023
Q4 		$719K Buy
+215,902
New +$578K 0.17% 112

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return